Kjaeldgaard A, Larsson B, Astedt B
J Clin Pathol. 1984 Oct;37(10):1153-6. doi: 10.1136/jcp.37.10.1153.
To evaluate the rat as an experimental model for plasminogen activator research, the ability of antibodies specific for human tissue type plasminogen activator and urokinase to suppress the plasminogen activator activity in whole plasma and in the vessel wall was studied in both rat and man. Plasminogen activator activity in plasma was assayed on fibrin plates containing plasminogen. Plasminogen activator in the vessel wall was shown by the fibrin side technique. Antibodies against human tissue type melanoma cell activator and urokinase were raised in goats and mixed into the fibrin film or the fibrin plates. In both species antibodies to melanoma cell activator were able to suppress the plasminogen activator activity completely in plasma and in the vessel wall. Anti-urokinase, however, had no suppressing effect. In rat plasma the inhibitory effect on the fibrinolytic activity was seen only with high concentrations of antibodies against melanoma cell activator, which suggests that rat plasminogen activator in plasma and vessel walls is similar to, but not identical with, human tissue type plasminogen activator.
为了评估大鼠作为纤溶酶原激活剂研究的实验模型,在大鼠和人类中研究了针对人组织型纤溶酶原激活剂和尿激酶的特异性抗体抑制全血和血管壁中纤溶酶原激活剂活性的能力。血浆中的纤溶酶原激活剂活性在含有纤溶酶原的纤维蛋白平板上进行测定。血管壁中的纤溶酶原激活剂通过纤维蛋白侧技术显示。针对人组织型黑色素瘤细胞激活剂和尿激酶的抗体在山羊体内产生,并混入纤维蛋白膜或纤维蛋白平板中。在这两个物种中,针对黑色素瘤细胞激活剂的抗体能够完全抑制血浆和血管壁中的纤溶酶原激活剂活性。然而,抗尿激酶没有抑制作用。在大鼠血浆中,仅在高浓度的抗黑色素瘤细胞激活剂抗体时才观察到对纤溶活性的抑制作用,这表明大鼠血浆和血管壁中的纤溶酶原激活剂与人类组织型纤溶酶原激活剂相似,但不完全相同。